Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)

Renal Failure

Volumn 32, Issue 6, 2010, Pages 753-756

  Bento, Diogo ^a   Mapril, Joana ^a   Rocha, Carla ^a   Marchbank, Kevin J ^b   Kavanagh, David ^c   Barge, Dawn ^d   Strain, Lisa ^e   Goodship, Timothy H J ^c   Meneses Oliveira, Carlos ^a  

^a HOSPITAL DE SANTA CRUZ   (Portugal)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical hemolytic uremic syndrome; Influenza A H1N1; Microangiopathy; Renal failure

Indexed keywords

ANTIBIOTIC AGENT; BILIRUBIN; CEFTRIAXONE; CLARITHROMYCIN; CORTICOSTEROID; HEMOGLOBIN; LACTATE DEHYDROGENASE; MEMBRANE PROTEIN; OSELTAMIVIR; PREDNISOLONE; TRANSMEMBRANE COMPLEMENT REGULATOR MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG; UREA;

ADOLESCENT; ARTICLE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD EXAMINATION; BLOOD TRANSFUSION; CASE REPORT; CONVALESCENCE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ERYTHROCYTE; FEVER; HEADACHE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOPTYSIS; HUMAN; HUMAN CELL; INFLUENZA A (H1N1); JAUNDICE; MALE; MEDICAL HISTORY; MUTATIONAL ANALYSIS; NOSE SMEAR; PLASMAPHERESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; UREA BLOOD LEVEL;

ADOLESCENT; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE;

EID: 77953593277     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.486491     Document Type: Article

References (18)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687.
2. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23(11):1957-1972.
3. Davison AM, Thomson D, Robson JS. Intravascular coagulation complicating influenza A virus infection. Br Med J. 1973; 1:654-655.
4. Asaka M, Ishikawa I, Nakazawa T, Tomosugi N, Yuri T, Suzuki K. Hemolytic uremic syndrome associated with influenza A virus infection in an adult renal allograft recipient: Case report and review of the literature. Nephron. 2000;84:258-266.
5. Watanabe T. Hemolytic uremic syndrome associated with influenza A virus infection. Nephron. 2001;89(3):359-360.
6. Caprioli J, Noris M, Brioschi S, et al.. Genetics of HUS: The impact of MCP, CFH and IF mutations on clinical presentation, response to treatment and outcome. Blood. 2006;108: 1267-1279.
7. Delvaeye M, Noris M, De Vriese A, et al.. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345-357.
8. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23(11):1957-1972.
9. Esparza-Gordillo J, Goicoechea de JE, Buil A, et al.. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14 (5):703-712.
10. Esparza-Gordillo J, Goicoechea de Jorge E, Garrido CA, et al.. Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol. 2006;43(11):1769-1775.
11. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al.. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400.
12. Ariceta G, Besbas N, Johnson S, et al.. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24:687-696.
13. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical Practice Guidelines for the management of atypical hemolytic uraemic syndrome in the United Kingdom. Br J Hematol. 2010; 148(1):37-47.
14. Beebe DP, Schreiber RD, Cooper NR. Neutralization of influenza virus by normal human sera: Mechanisms involving antibody and complement. J Immunol. 1983;130: 1317-1322.
15. Bjornson AB, Mellencamp MA, Schiff GM. Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis. 1991;143:1062-1066.
16. Varsano S, Kaminsky M, Kaiser M, Rashkovsky L. Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax. 2000;55:364-369.
17. Cooper NR. Complement and viruses. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York: Marcel Dekker; 1998:393-407.
18. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6(2): 132-142.